Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 12Esophageal Squamous Cell Carcinoma 11Pancreatic Neoplasms 8Stomach Neoplasms 4Colorectal Neoplasms 3Pancreatic cancer, adult 2Squamous Cell Carcinoma of Anal Canal 1Resectable Pancreatic Cancer 1Pancreatic Cancer Resectable 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer 1Esophageal 1Advanced Pancreatic Cancer 1Advanced Esophageal 1Advanced Colorectal Cancer 1Adenocarcinoma 1

Interventions

Gemcitabine 3folfirinox 2Cisplatin 2paricalcitol 1nimotuzumab 1Taxes 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Chemotherapy, Adjuvant 1Chemoradiotherapy, Adjuvant 1Albumin-Bound Paclitaxel 1Adjuvants, Immunologic 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Pancreatic Cancer × nimotuzumab × Gastrointestinal × Clear all
NCT06363084 2024-04-12

A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer

Ruijin Hospital

Completed
64 enrolled
Gastrointestinal

Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡